Skip to content
Facebook
Twitter
Linkedin
Pharmaceutical
INM-901 for Alzheimer’s Disease
INM-089 for Age-related Macular Degeneration
INM-755 for Epidermolysis Bullosa
INM-088 for Glaucoma
Novel Analogs
Manufacturing
BayMedica – Rare Cannabinoid Ingredients
Cannabinoid Manufacturing Expertise
IntegraSyn™ Cannabinoid Manufacturing
Investors
News Releases
Events
Stock Information
Corporate Governance
Financials & AGM Materials
Filings
Presentations
Media and Videos
Investor Contact
Corporate
Management
Board of Directors
Scientific Advisors
Partners and Collaborators
Careers
Contact
Learn
Pharmaceutical
INM-901 for Alzheimer’s Disease
INM-089 for Age-related Macular Degeneration
INM-755 for Epidermolysis Bullosa
INM-088 for Glaucoma
Novel Analogs
Manufacturing
BayMedica – Rare Cannabinoid Ingredients
Cannabinoid Manufacturing Expertise
IntegraSyn™ Cannabinoid Manufacturing
Investors
News Releases
Events
Stock Information
Corporate Governance
Financials & AGM Materials
Filings
Presentations
Media and Videos
Investor Contact
Corporate
Management
Board of Directors
Scientific Advisors
Partners and Collaborators
Careers
Contact
Learn
Other definitive proxy statements – 10/28/2022
Post navigation
←
Previous Filings
Next Filings
→
Leave a Reply
Cancel reply
You must be
logged in
to post a comment.
Sign up to receive emails from InMed Pharmaceuticals
"
*
" indicates required fields
Name
*
First name
*
Last name
*
Email
*
Consent
*
By providing your e-mail address, you consent to receive news, press releases, quarterly and annual reports, presentations and other information from InMed Pharmaceuticals Inc. You can unsubscribe at any time.
CAPTCHA
